Repositorio Dspace

Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices?

Mostrar el registro sencillo del ítem

dc.contributor.author Mahe, Isabelle
dc.contributor.author Sterpu, Raluca
dc.contributor.author Bertoletti, Laurent
dc.contributor.author López-Jiménez, Luciano
dc.contributor.author Joan, Meritxell-Mellado
dc.contributor.author Trujillo-Santos, Javier
dc.contributor.author Ballaz, Aitor
dc.contributor.author Hernández-Blasco, Luis-Manuel
dc.contributor.author Javier-Marchena, Pablo
dc.contributor.author Monreal, Manuel
dc.date.accessioned 2026-10-21T06:12:29Z
dc.date.available 2026-10-21T06:12:29Z
dc.date.issued 2015-06-15
dc.identifier.citation Mahé I, Sterpu R, Bertoletti L, López-Jiménez L, Mellado Joan M, Trujillo-Santos J, et al. Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices? Lonser RR, editor. PLoS ONE. 15 de junio de 2015;10(6):e0128741. doi:10.1371/journal.pone.0128741
dc.identifier.issn 1932-6203
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/28766
dc.description.abstract Current guidelines of antithrombotic therapy suggest early initiation of vitamin K antagonists (VKA) in non-cancer patients with venous thromboembolism (VTE), and long-term therapy with low-molecular weight heparin (LMWH) for those with cancer. We used data from RIETE (international registry of patients with VTE) to report the use of long-term anticoagulant therapy over time and to identify predictors of anticoagulant choice (regarding international guidelines) in patients with- and without cancer. Among 35,280 patients without cancer, 82% received long-term VKA (but 17% started after the first week). Among 4,378 patients with cancer, 66% received long term LMWH as monotherapy. In patients without cancer, recent bleeding (odds ratio [OR] 2.70, 95% CI 2.26-3.23), age >70 years (OR 1.15, 95% CI 1.06-1.24), immobility (OR 2.06, 95% CI 1.93-2.19), renal insufficiency (OR 2.42, 95% CI 2.15-2.71) and anemia (OR 1.75, 95% CI 1.65-1.87) predicted poor adherence to guidelines. In those with cancer, anemia (OR 1.83, 95% CI 1.64-2.06), immobility (OR 1.51, 95% CI 1.30-1.76) and metastases (OR 3.22, 95% CI 2.87-3.61) predicted long-term LMWH therapy. In conclusion, we report practices of VTE therapy in real life and found that a significant proportion of patients did not receive the recommended treatment. The perceived increased risk for bleeding has an impact on anticoagulant treatment decision.
dc.language.iso eng
dc.rights Atribución/Reconocimiento 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by/4.0/deed.es *
dc.subject.mesh Aged
dc.subject.mesh Aged, 80 and over
dc.subject.mesh Anticoagulants/therapeutic use
dc.subject.mesh Drug Prescriptions/statistics & numerical data
dc.subject.mesh Female
dc.subject.mesh Fibrinolytic Agents/therapeutic use
dc.subject.mesh Follow-Up Studies
dc.subject.mesh Guideline Adherence
dc.subject.mesh Heparin, Low-Molecular-Weight
dc.subject.mesh Humans
dc.subject.mesh Male
dc.subject.mesh Middle Aged
dc.subject.mesh Neoplasms/complications
dc.subject.mesh Time Factors
dc.subject.mesh Venous Thromboembolism/diagnosis/drug therapy/etiology
dc.subject.mesh Vitamin K/antagonists & inhibitors
dc.title Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices?
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 26076483
dc.relation.publisherversion https://dx.plos.org/10.1371/journal.pone.0128741
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1371/journal.pone.0128741
dc.journal.title Plos One


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta